Hospital data reveals a sharp rise in consultations related to hormonal health, erectile dysfunction and male fertility, highlighting growing awareness among younger men.
Under the agreement, Apotex’s branded division, Searchlight Pharma, will seek regulatory approval and handle marketing and distribution in Canada
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
Highlights strong Vibegron results in older men & real-world prostate cancer insights
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Subscribe To Our Newsletter & Stay Updated
